@article {Wang2021.04.20.21255480, author = {Hannah Wang and Jacob A. Miller and Michelle Verghese and Mamdouh Sibai and Daniel Solis and Kenji O. Mfuh and Becky Jiang and Naomi Iwai and Marilyn Mar and ChunHong Huang and Fumiko Yamamoto and Malaya K. Sahoo and James Zehnder and Benjamin A. Pinsky}, title = {Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance}, elocation-id = {2021.04.20.21255480}, year = {2021}, doi = {10.1101/2021.04.20.21255480}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Emergence of SARS-CoV-2 variants with concerning phenotypic mutations is of public health interest. Genomic surveillance is an important tool for pandemic response, but many laboratories do not have the resources to support population-level sequencing. We hypothesized that a spike genotyping nucleic acid amplification test (NAAT) could facilitate high-throughput variant surveillance.Methods We designed and analytically validated a one-step multiplex allele-specific reverse transcriptase polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein mutations (L452R, E484K, N501Y). Assay specificity was validated with next-generation whole-genome sequencing. We then screened a large cohort of SARS-CoV-2 positive specimens from our San Francisco Bay Area population.Results Between December 1, 2020 and March 1, 2021, we screened 4,049 unique infections by genotyping RT-qPCR, with an assay failure rate of 2.8\%. We detected 1,567 L452R mutations (38.7\%), 34 N501Y mutations (0.84\%), 22 E484K mutations (0.54\%), and 3 (0.07\%) E484K+N501Y mutations. The assay had near-perfect (98-100\%) concordance with whole-genome sequencing in a validation subset of 229 specimens, and detected B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants, among others. The assay revealed rapid emergence of L452R in our population, with a prevalence of 24.8\% in December 2020 that increased to 62.5\% in March 2021.Conclusions We developed and clinically implemented a genotyping RT-qPCR to conduct high-throughput SARS-CoV-2 variant screening. This approach can be adapted for emerging mutations and immediately implemented in laboratories already performing NAAT worldwide using existing equipment, personnel, and extracted nucleic acid.Summary / Key Points Emergence of SARS-CoV-2 variants with concerning phenotypes is of public health interest. We developed a multiplex genotyping RT-qPCR to rapidly detect L452R, E484K, and N501Y with high sequencing concordance. This high-throughput alternative to resource-intensive sequencing enabled surveillance of L452R emergence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with Stanford institutional review board approval (protocol 48973), and individual consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript is available upon request.}, URL = {https://www.medrxiv.org/content/early/2021/05/01/2021.04.20.21255480}, eprint = {https://www.medrxiv.org/content/early/2021/05/01/2021.04.20.21255480.full.pdf}, journal = {medRxiv} }